Carboplatin and vinorelbine in advanced non-small-cell lung cancer

Abstract

 A total of 32 patients with advanced non-small-cell lung cancer were treated with carboplatin (350 mg/m2, day 1) and vinorelbine (days 1 and 8) every 28 days. A response rate of 28% (95% confidence limits 12.5 – 43.7%) was observed. The activity of this combination was demonstrated in an outpatient setting with acceptable toxicity. 
DOI: 10.1007/s002800050436

2 Figures and Tables

Topics

  • Presentations referencing similar topics